Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature

Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypogl...

Descripción completa

Detalles Bibliográficos
Autores principales: Oziel-Taieb, Sandrine, Maniry-Quellier, Jemima, Chanez, Brice, Poizat, Flora, Ewald, Jacques, Niccoli, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063459/
https://www.ncbi.nlm.nih.gov/pubmed/35518928
http://dx.doi.org/10.3389/fendo.2022.860614
_version_ 1784699169977401344
author Oziel-Taieb, Sandrine
Maniry-Quellier, Jemima
Chanez, Brice
Poizat, Flora
Ewald, Jacques
Niccoli, Patricia
author_facet Oziel-Taieb, Sandrine
Maniry-Quellier, Jemima
Chanez, Brice
Poizat, Flora
Ewald, Jacques
Niccoli, Patricia
author_sort Oziel-Taieb, Sandrine
collection PubMed
description Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
format Online
Article
Text
id pubmed-9063459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90634592022-05-04 Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature Oziel-Taieb, Sandrine Maniry-Quellier, Jemima Chanez, Brice Poizat, Flora Ewald, Jacques Niccoli, Patricia Front Endocrinol (Lausanne) Endocrinology Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma. Frontiers Media S.A. 2022-04-19 /pmc/articles/PMC9063459/ /pubmed/35518928 http://dx.doi.org/10.3389/fendo.2022.860614 Text en Copyright © 2022 Oziel-Taieb, Maniry-Quellier, Chanez, Poizat, Ewald and Niccoli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Oziel-Taieb, Sandrine
Maniry-Quellier, Jemima
Chanez, Brice
Poizat, Flora
Ewald, Jacques
Niccoli, Patricia
Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title_full Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title_fullStr Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title_full_unstemmed Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title_short Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
title_sort pasireotide for refractory hypoglycemia in malignant insulinoma- case report and review of the literature
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063459/
https://www.ncbi.nlm.nih.gov/pubmed/35518928
http://dx.doi.org/10.3389/fendo.2022.860614
work_keys_str_mv AT ozieltaiebsandrine pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature
AT maniryquellierjemima pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature
AT chanezbrice pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature
AT poizatflora pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature
AT ewaldjacques pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature
AT niccolipatricia pasireotideforrefractoryhypoglycemiainmalignantinsulinomacasereportandreviewoftheliterature

Ejemplares similares